Iterum Therapeutics PLC (ITRM)
1.15
+0.03
(+2.68%)
USD |
NASDAQ |
Jul 05, 16:00
1.15
0.00 (0.00%)
After-Hours: 20:00
Iterum Therapeutics Research and Development Expense (Annual): 39.99M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 39.99M |
| December 31, 2022 | 17.62M |
| December 31, 2021 | 10.71M |
| December 31, 2020 | 21.07M |
| Date | Value |
|---|---|
| December 31, 2019 | 90.77M |
| December 31, 2018 | 68.65M |
| December 31, 2017 | 25.50M |
| December 31, 2016 | 10.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
10.71M
Minimum
2021
90.77M
Maximum
2019
36.03M
Average
21.07M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Alkermes PLC | 270.81M |
| Jazz Pharmaceuticals PLC | 849.66M |
| Medtronic PLC | 2.735B |
| Perrigo Co PLC | 122.50M |
| Trinity Biotech PLC | 4.379M |